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Abstract A large number of ventilation strategies are now
available for the neonate. This review has focused on new
information, that is, studies published since 2000 and the
implication of their results for current clinical practice.
Meta-analysis of randomised trials has demonstrated that
assist control and synchronous intermittent mandatory
ventilation (SIMV) shortens the duration of ventilation
only if started in the recovery rather than the early stage of
respiratory disease. A recent randomised trial demonstrated
pressure-regulated volume control ventilation may also
have no advantages if started early. Weaning by SIMV
with pressure support is better (reducing oxygen dependen-
cy) than SIMV alone. Meta-analysis of volume-targeted
ventilation demonstrated significant reductions in the
duration of ventilation and pneumothorax, but the trials
were small and of different designs. Volume guarantee may
provide more consistent blood gas control. The level of
volume targeting appears to be crucial to the success of this
technique. Meta-analysis of randomised trials of prophy-
lactic high-frequency oscillation trials has shown a modest
reduction in bronchopulmonary dysplasia. Randomised
trials have failed to confirm the advantages of nasal
continuous positive airway pressure (NCPAP) seen in
various non-randomised studies; however, the randomised
trials reported to date have been small. Inhaled nitric oxide
(NO) does not improve the outcome of prematurely born
infants with severe respiratory failure, but early low-dose
prolonged iNO appears to have benefits that merit further
testing. More randomised trials with long-term outcomes
are required to identify the optimal ventilation strategy(ies)
for the neonate.
Keywords Continuous positive airway pressure .





CPAP Continuous positive airway pressure
HFOV High-frequency oscillation ventilation
HHFNC Humidified high-flow nasal cannula
ICH Intracranial haemorrhage
iNO Inhaled nitric oxide
IPPV Intermittent positive pressure ventilation
MAP Mean airway pressure
PAV Proportional assist ventilation
PS Pressure support
PTV Patient trigger ventilation
PVL Periventricular leukomalacia
SIMV Synchronised intermittent mandatory ventilation




Eur J Pediatr (2007) 166:991–996
DOI 10.1007/s00431-007-0513-0
Source of funding and grants: Atul Sharma is supported by the
WellChild Trust.
A. Greenough :A. Sharma




Children Nationwide Regional Neonatal Intensive Care Centre,
King’s College Hospital,
4th floor, Golden Jubilee Wing,
London SE5 9PJ, UK
e-mail: anne.greenough@kcl.ac.uk
Introduction
A large number of ventilation strategies are now available for
the neonate. The quality of evidence to support particular
strategies, however, varies. This review has focused in
particular on new information – that is, on the results of
clinical studies published since 2000 – and discusses the
implications of those results for current practice.
Patient-triggered ventilation (PTV)
PTV was reintroduced into neonatal intensive care in the
1980s, initially as assist/control (A/C, inflations triggered
by every spontaneous breath that exceeded the critical
trigger threshold) and synchronised intermittent mandatory
ventilation (SIMV, only the preset number of inflations are
triggered regardless of the infant’s spontaneous respiratory
rate).It was hoped that these ventilation modes would be
more likely to promote synchrony between the infant and
ventilator inflations and hence reduce airleaks and broncho-
pulmonary dysplasia (BPD). Unfortunately, meta-analysis of
the randomised trials [16] demonstrated no significant
differences in the rates of BPD, severe intracranial hemor-
rhage (ICH), air leaks and mortality rates according to
ventilation mode. PTV was associated with a shorter du-
ration of ventilation, but this was only seen in infants re-
covering from respiratory distress rather than in those in the
acute stages. Similarly, in a recent randomised trial [9] in
which infants were randomised at less than 6 h of age,
pressure-regulated volume control ventilation (a synchro-
nised, pressure limited A/C mode that sequentially varies
the delivered pressure to approximate a target inspiratory
tidal volume) compared to SIMV was not associated with an
increased number of babies being extubated at 14 days.
Newer modes of triggered ventilation have now been
introduced. During pressure support (PS), not only the
initiation (as with A/C and SIMV) but also the termination
of ventilator inflation is determined by the infant’s spontane-
ous respiratory efforts. PS may have advantages when used
as a weaning mode [36]. In a randomised trial of 107 infants
of birthweights between 500 and 1000 gm, weaning by
SIMV plus PS compared to weaning by SIMV (reduction in
rate) alone resulted in infants of birthweights between 700
and 1000 gm requiring significantly fewer days on sup-
plemental oxygen (41 vs. 58 days) [36]. During proportional
assist ventilation (PAV), the applied pressure is servo-
controlled throughout each spontaneous breath, and the
frequency, timing and rate of lung inflation are controlled
by the patient. The applied pressure increases in proportion to
the tidal volume and inspiratory flow generated by the
patient, which can be enhanced to reduce the work of
breathing. In a randomised study involving extremely low
birthweight infants with evolving BPD, in which 4-h periods
of different ventilation modes were compared, gas exchange
was maintained at lower mean and peak pressures on PAV
compared to A/C or SIMV, but desaturations lasted longer on
PAV [41]. These data [41] emphasise that backup con-
ventional ventilation breaths must be provided during PAV
to prevent apnoea-related desaturations [41]. A newly
developed backup support (SPO2-sensitive adaptive backup
support) has been developed, and the use of this adaptive
backup support with pulse oximetry-guided operation was
shown to reduce the incidence and duration of oxygen
desaturations [19].
Volume-targeted ventilation (VTV)
Many ventilator types designed for use in neonates can deli-
ver a preset tidal volume; such systems are known as volume-
targeted ventilation (VTV). There are different forms of VTV
[28]. During volume controlled (VC) or volume support
(VS) ventilation, the desired tidal volume is selected, and
the duration of inflation depends on the time taken for the
volume to be delivered, which is adjusted by changes in the
inspiratory flow rate.
During volume guarantee (VG) ventilation, a preset ex-
piratory tidal volume is selected, but the preset inspiratory
time determines the duration of inflation. During volume
limited ventilation, the pressure support for any inflation is
aborted if the measured inspired tidal volume exceeds a
preset upper limit. During volume control inflation there is a
breath-by-breath servo-controlled flow, which is constant
during inspiration so that the required volume is delivered
over the set inspiratory time. Ventilator manufacturers have
used different strategies to achieve VTV. The SLE 5000 and
Bear Cub 750psv deliver targeted tidal or volume limited
ventilation, the Draeger Babylog 8000 delivers VGV, the
VIP BIRD and Avea deliver VC (or BS) ventilation and the
Stephanie Paediatric ventilator delivers VC inspiration. In
VTV, there are differences according to ventilator type in the
delivered peak pressure, inflation time, airway pressure
waveform and, hence, mean airway pressure [43]. In clinical
studies, VG levels between 4 and 6 ml/kg have been used,
but there is evidence to suggest that it is more appropriate
to use the higher level. Greater lung inflammation was
demonstrated when a volume of 3 rather than 5 ml/kg was
used with SIPPV during the acute phase of respiratory dis-
tress syndrome (RDS) [25]. A level of 6 but not 4.5 ml/kg
reduced the duration of hypoxemic episodes during SIMV
in one study [34], and in another study, 6 ml/kg compared
to 4 or 5 m/kg was associated with the lowest work of
breathing [42].
Meta-analysis of the results of four randomised trials
[28] demonstrated that VTV was associated with significant
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reductions in the duration of ventilation and the rate of
pneumothorax, but not death or BPD. The trials, however,
were small; in total, only 178 infants were included in the
meta-analysis. A further limitation was that different VTV
modes were used in the four trials. In a subsequent ran-
domised trial, infants with birthweights of 600–1500 gm
supported by VC ventilation were compared to those
supported by time-cycled pressure limited ventilation [45];
the former reached a predetermined success criterion earlier
than the latter, with the difference reaching statistical
significance only in babies with a birthweight less than
1000 gm. There were, however, no other advantages dem-
onstrated. In another recent randomised study, VG with
SIMV rather than SIMV alone was more effective in
maintaining desirable carbon dioxide tensions in infants of
greater than 25 weeks of gestational age, but was ineffective
in more immature infants [7]. In very low birthweight
(VLBW) infants with frequent hypoxaemic episodes, vol-
ume rather than pressure controlled SIMV was associated
with less bradycardias, but it did not decrease the time spent
at an oxygen saturation of less than 80% [20]. Evidence on
whether the use of VG in combination with PS improves
outcomes, particularly in terms of the effect on lung
inflammation, is conflicting [10, 26]. In one study, the only
advantage of using VG with PS was that less blood gas
monitoring was required [31].
High-frequency oscillatory ventilation (HFOV)
During HFOV, small tidal volumes are delivered at frequen-
cies of between 8 and 15 Hz. Certain oscillators display the
volume delivered, but frequency can affect the accuracy of the
displayed volume [24]. There have been at least 11 trials in
which infants have been randomised to receive HFOV or
standard ventilation techniques in the first 24 h after birth.
Meta-analysis of their results [18] demonstrated that HFOV
had no significant effect on mortality and only a modest
reduction in BPD in terms of survivors at term; however, it
had no statistically significant effect on short-term neurolog-
ical abnormality, ICH or PVL. The three most recently
reported randomised trials included in the meta-analysis
yielded different results. Moriette et al. [29] reported that
HFOV was associated with a trend towards an increase in
severe ICH; the oscillator they employed has not been used
in any of the other randomized trials. Courtney et al. [8]
reported that HFOV reduced the combined outcome of BPD
and death, but the randomized comparator group was sup-
ported by SIMV, which may have put them at a disadvantage
as the work of breathing is increased at low SIMV rates. In
the third trial [21] (United Kingdom Oscillation, UKOS
trial), 799 infants below 29 weeks of gestation were
randomised within 1 h of birth to HFOV or standard venti-
lation techniques, and no benefits or disadvantages of HFOV
were noted. In addition, the follow-up assessments of the
UKOS survivors also demonstrated no significant differ-
ences in lung function results at 1 year of age [47] or in
respiratory or neurodevelopmental outcome at 2 years of
corrected age [27]. HFOV is also used to “rescue” infants
with severe respiratory failure. Mean airway pressure (MAP)
is increased in the hope of optimising lung volume and
hence oxygenation. An initial improvement in oxygenation
in response to HFOV, however, does not guarantee a normal
neurodevelopmental outcome at 2 years in very prematurely
born infants [12].
Non-invasive respiratory support
Continuous positive airway pressure (CPAP) can be deliv-
ered by a headbox, facemask, nasaopharyngeal or endotra-
cheal tube, single or binasal prongs. Nasal CPAP is
considered by many as a gentler form of respiratory support,
but it does have adverse effects, including nasal trauma in
between 20 and 32% of all infants. It had been suggested that
nasal trauma might particularly be a problem with dual
prongs, but randomised studies have demonstrated no sig-
nificant differences in the incidence of trauma between
binasal prongs, a nasaopharyngeal tube [5], binasal prongs
or facemask [51]. The only significant relationship to
trauma in one series was CPAP duration [51]. Newer forms
of CPAP include variable flow and bubble CPAP. Variable
CPAP has been associated with better lung recruitment than
continuous flow CPAP and a lower work of breathing.
Lung overdistension, however, may occur in infants with
mild disease if variable flow CPAP levels greater than 6 cm
H2O are used. During bubble CPAP, the pressure in the
device is generated by a continuous flow of gas, with the
distal end placed a set depth under water; the bubbles create
pressure oscillations, which are transmitted back to the
airway opening [33]. Clinical studies of bubble CPAP have
yielded mixed results [30].
Early CPAP is now used in many centres in preference to
early intubation and intermittent positive pressure ventila-
tion (IPPV). Although early CPAP can be successful in
very immature infants [4], it is more likely to fail in that
group [1]. This was highlighted by a recent experience in
Columbia [1]: whereas 95% of infants between 26 and
28 weeks were initially started on CPAP in the delivery
room and 78% were successfully supported only by this
technique, 69% of infants of 23–25 weeks were treated
initially with CPAP, but only 31% could be maintained on it
[1]. In a nonrandomised comparison, the application of
CPAP in the delivery suite in one centre compared to
intubation in the other centre was associated with fewer
infants requiring supplementary oxygen at 40 weeks post-
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menstrual age (P.A.) [48]. Randomised trials, however,
have not confirmed the apparent benefits of CPAP reported
in nonrandomised studies. Meta-analysis of two published
randomised trials examining prophylactic CPAP com-
menced soon after birth demonstrated no significant differ-
ences in the use of mechanical ventilation or the incidence of
BPD [46]. In addition, transient intubation for surfactant
administration rather than nasal (n)CPAP was associated
with fewer infants requiring mechanical ventilation and a
lower concentration of supplementary oxygen [35]. Pro-
phylactic CPAP (instituted within 30 min of birth) also
appears not be more efficacious than rescue CPAP, which is
applied when the inspired oxygen requirement is greater
than 40%, as no significant differences with regard to the
need for surfactant treatment or mechanical ventilation were
seen in a randomised trial including 230 infants of
gestational ages between 29 and 31 weeks [37]. It has been
suggested that the use of early nCPAP may improve neuro-
logical outcome, as fewer cases of intraventricular haemor-
rhage (IVH) and abnormal neurodevelopment were seen at
6 months of age following the systematic application of
early nCPAP; however, the comparison was made to
historical controls [50]. In a national Danish cohort study
[17], comparison at age 5 years of all 269 survivors with a
birthweight below 1000 gm or a gestational age at birth of
less than 28 weeks treated with early nCPAP revealed that
these children have an intellectual development similar to
that of a reference group of 76 term-born children [17].
Meta-analysis of the results of post-extubation rando-
mised trials has demonstrated that CPAP significantly re-
duced the need for additional respiratory support (RR: 0.62,
0.49–0.77), but not the need for endotracheal intubation
(RR: 0.93, 0.72–1.19) or supplemental oxygen requirement
at 28 days (RR: 1.00, 0.81–1.24) [11]. Indeed, in a
subsequently reported prospective randomised trial involving
97 infants, 24 h of CPAP post-extubation compared to ex-
tubation directly into a headbox was not associated with a
significant reduction in reventilation [32].
An alternative to the use of nCPAP is humidified high-flow
nasal cannula (HHFNC) devices. The use of HHFNC has
increased in many centres because of its ease of use and
perceived improved tolerance with minimal nasal trauma
compared to nCPAP [44]. There has, however, been concern
regarding its imprecise regulation, the generation of pressure
that might occur at higher flows – particularly in the smallest
of infants – as well as a potential for increased work of
breathing compared to that experience on nCPAP. In a small
randomised trial [39], however, no increased work of
breathing was demonstrated in infants less than 2 kg on
HHFNC (3–5 Lpm) compared to 6 cm H2O nCPAP. There
have been concerns regarding increased Gram-negative
bacteraemia, specifically R. picketti [6], when using the
Vapotherm 2001, a device delivering high flow which,
consequently, was recalled [44]. A positive association
between nasal cannula CPAP and late-onset Gram-negative
blood infections in VLBW infants has also been reported and
attributed to nasal trauma [15]. The introduction of humid-
ified high-flow nasal cannula (HHFNC) into two tertiary
centres was associated with an increase (not significant) of
Gram-negative bacteraemia [44]. In a randomised trial,
however, HHFNC maintained a normal mucosa better than
standard HFNC, but the relative impact of the devices on
infection rates remains to be tested [49].
A variety of nasal ventilation modes, including IPPV,
SIMV or HFOV delivered by nasal prongs are being used,
and there is suggestion of benefit. Extubation immediately
after surfactant administration to SNIPPV rather than con-
tinuing on conventional ventilation was associated with a
decreased need for supplementary oxygen and shorter du-
rations of intubation, parental nutrition and hospitalisation
[38]. Similarly, in another study, extubation to SNIPPV
rather than CPAP was associated with a shorter duration of
supplementary oxygen and a lower incidence of BPD (73
vs. 40%) [23]. Neither study [23, 38], however, was ran-
domised. Older evidence is from anecdotal studies or trials
with short-term outcomes; consequently, the true benefit (or
the reverse) of these forms of support remains to be
appropriately investigated.
Inhaled nitric oxide (iNO)
iNO, administered directly to the airway, is a selective pul-
monary vasodilator used to treat hypoxemic respiratory
failure associated with pulmonary hypertension of the
newborn. Meta-analysis of the results of randomised trials
has demonstrated that iNO reduces death or the need for
extracorporeal membrane oxygenation (ECMO) in infants
born at or near term, but the positive effect is the ECMO
requirement [13]. Meta-analysis [3] of the results of seven
trials in premature infants demonstrated that iNO had only
short-term positive effects on oxygenation but no signifi-
cant effects on mortality, BPD or ICH. In infants with
severe respiratory failure, the use of iNO was associated
with prolongation of intensive care and increased cost of
care without clear beneficial effects [14]. In contrast, in one
study [40], iNO was associated with a significant reduction
in the combined outcome of death and BPD (RR: 0.76,
0.60–0.97) and in grade 3 and 4 IVH (RR: 0.51, 0.27–
0.97); sub-analysis demonstrated the advantages were seen
in the infants with relatively mild disease. Recently, two
further positive iNO studies have been reported; the results
of both suggest that prolonged therapy with iNO may be
efficacious. In one of these studies [22], although there was
no overall reduction in death or BPD in infants with
birthweights between 1000 and 1250 g, low-dose (5 ppm)
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iNO given for 21 days or until extubation reduced the
incidence of BPD by 50% and was associated with a lower
rate of the combined outcome of ICH, periventricular
leukomalacia (PVL) and ventriculomegaly. In the second
trial [2], iNO was associated with a significant increase in
survival without BPD (43.9 vs. 36.8%), with the minimum
treatment exposure being 24 days. The infants who
received iNO were discharged sooner and received supple-
mental oxygen for a shorter time. Post hoc analysis dem-
onstrated that the positive effects were seen in infants
enrolled at 7–14 days but not at 15–21 days, and they were
restricted to infants with less severe lung disease. There are
ongoing trials to determine whether early, low-dose pro-
longed iNO will improve the long-term pulmonary outcome
of immature infants with relatively mild initial disease.
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